Feb 22, 2024
In this episode, host Shikha Jain, MD, speaks
with Ashley Sumrall, MD, about advocacy outside of
their oncology practices and organizations, what lies ahead for the
field of neuro-oncology and more.
• Welcome to another exciting episode of Oncology
Overdrive :58
• About Sumrall 1:16
• The interview 2:54
• How did you end up in the neuro-oncology space?
3:21
• As a neuro-oncologist, how do you stay up-to-date
with neurology, oncology and medicine?
7:28
• Is there a difference in the way you interact with a
neuro-oncologist versus a medical oncologist?
8:58
• What drove you to get into the advocacy space?
10:09
• Do you predominantly do advocacy work through ASCO,
or do you do it through other avenues as well?
12:20
• If someone is interested in getting involved in
becoming an advocate
with ASCO, on the local level or on the national level, what is
the best way for them to start that process?
15:24
• How do you talk to people in and outside of
organizations about current situations facing health care?
19:40
• If people are interested in learning more about the
AMA or getting involved with an organization like the AMA, how can
they do so? 22:31
• What do you see coming down the pipeline that you
think is going to transform the neuro-oncology space?
27:16
• If someone could only listen to the last minute of
this episode, what would you want them to take away?
30:04
• How to contact Sumrall
32:13
• Thanks for listening
32:56
Ashley L. Sumrall, MD, is a neuro-oncologist
practicing at Levine Cancer Institute in Charlotte, NC.
We’d love to hear from you! Send your comments/questions to Dr.
Jain at oncologyoverdrive@healio.com.
Follow Healio on X, formerly known as Twitter, and LinkedIn:
@HemOncToday and
https://www.linkedin.com/company/hemonctoday/.
Follow Dr. Jain on X, formerly known as Twitter:
@ShikhaJainMD. Sumrall can be reached on X, formerly known as
Twitter:
@AshleySumrallMD.
Disclosures: Jain reports no relevant financial
disclosures. Sumrall reports receiving funding from Bristol-Myers
Squibb, Exelixis, Kura Oncology, Novocure and Oncoceutics, and
being a consultant for Abbvie, Athenex, Bayer, Exelixis and
Novocure.